NAV
$23.08
AUM
$36.7M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.64
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +33.81% | +16.64% | +30.99% | +57.04% | +10.08% | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | CMPS | Compass Pathways PLC ADR | 11.87% |
| 2 | ATAI | AtaiBeckley Inc | 10.03% |
| 3 | DFTX | Definium Therapeutics Inc Ordinary Shares | 8.62% |
| 4 | RLMD | Relmada Therapeutics Inc | 7.80% |
| 5 | NRXP | NRX Pharmaceuticals Inc Ordinary Shares | 7.60% |
| 6 | GHRS | GH Research PLC | 6.11% |
| 7 | NBIX | Neurocrine Biosciences Inc | 4.74% |
| 8 | DRUG.CN | Bright Minds Biosciences Inc Ordinary Shares | 4.64% |
| 9 | ALKS | Alkermes PLC | 4.54% |
| 10 | ABBV | AbbVie Inc | 3.70% |
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Inception Date: 2021-09-15